Hepatobiliary Center, Paul Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Villejuif, France.
Liver Transpl. 2011 Oct;17(10):1159-66. doi: 10.1002/lt.22372.
Several donor and graft characteristics are associated with higher failure rates for deceased donor liver transplantation (LT). The influence of reversible cardiac arrest in the donor on these failure rates is unclear because of scarce and inconsistent data. The aim of this study was to determine whether reversible cardiac arrest in the donor could affect the early postoperative outcome of LT. From January 2008 to February 2010, 165 patients underwent LT, and they were retrospectively divided into 2 groups: a cardiac arrest group (34 patients who received grafts from donors who had experienced reversible cardiac arrest before organ procurement) and a control group (131 patients who received grafts from donors without a history of reversible cardiac arrest). The postoperative complications and the graft and recipient outcomes were prospectively recorded for all the patients. Graft failure was defined as death or the need for retransplantation within 90 days of LT. Donors in the cardiac arrest group displayed higher serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels than donors in the control group [AST: 104 (19-756) versus 42 IU/L (10-225 IU/L), P < 0.001; ALT: 73 (13-869) versus 29 IU/L (6-549 IU/L), P < 0.001]. However, no difference in the graft failure rates was found between the 2 groups (11.8% versus 8.4%, P = 0.51). The biological parameters 5 and 7 days after LT and the peak AST/ALT levels were similar for the 2 groups. Furthermore, the 2 groups had similar graft and patient survival rates at the 6-month mark (87% and 88%, respectively). In conclusion, our study shows that brief and reversible cardiac arrest in organ donors does not affect post-LT allograft survival and function, even though liver function test values are higher for these donors. However, the risk of using these grafts needs to be balanced against the potential benefits for the recipients.
一些供体和移植物的特征与死亡供体肝移植(LT)的更高失败率相关。由于数据稀缺且不一致,供体可逆性心脏骤停对这些失败率的影响尚不清楚。本研究的目的是确定供体的可逆性心脏骤停是否会影响 LT 的术后早期结果。从 2008 年 1 月至 2010 年 2 月,165 名患者接受了 LT,并将他们回顾性地分为两组:心脏骤停组(34 名患者,其供体在器官采集前经历过可逆性心脏骤停)和对照组(131 名患者,其供体没有可逆性心脏骤停史)。所有患者均前瞻性记录术后并发症以及移植物和受者的结果。移植物失功定义为 LT 后 90 天内死亡或需要再次移植。心脏骤停组供体的血清天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)水平高于对照组[AST:104(19-756)与 42IU/L(10-225IU/L),P<0.001;ALT:73(13-869)与 29IU/L(6-549IU/L),P<0.001]。然而,两组之间的移植物失功率没有差异(11.8%与 8.4%,P=0.51)。两组 LT 后 5 天和 7 天的生物学参数和 AST/ALT 峰值相似。此外,两组在 6 个月时的移植物和患者存活率相似(分别为 87%和 88%)。总之,我们的研究表明,器官供体短暂和可逆性心脏骤停不会影响 LT 后移植物的存活和功能,尽管这些供体的肝功能试验值较高。然而,使用这些移植物的风险需要与受者的潜在益处相平衡。